跳至主要内容
临床试验/NCT05785221
NCT05785221进行中(未招募)不适用

Exploratory Personalized Lifestyle Intervention on Metabolic Homeostasis in Overweight or Obese Chinese Population

Chinese Academy of Sciences1 个研究点 分布在 1 个国家目标入组 117 人开始时间: 2023年3月2日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
117
试验地点
1
主要终点
Fasting and postprandial energy metabolic response at baseline and post-intervention

研究概览

简要总结

This is an exploratory controlled before-after study, which involves 112 participants, of whom 28 are with normal weight and 84 are overweight or obese. Twelve weeks of caloric-restriction dietary intervention will be conducted in the overweight or obese participants. Before and after the 12-week intervention, metabolic health will be characterized by metabolic homeostasis, determined via comprehensive measurements of dynamic postprandial metabolic responses to a standardized mixed macronutrient tolerance test (75 g glucose, 60 g fat, 20 g protein) in a whole-room indirect calorimeter. The objectives of this study are

  1. to characterize dynamic metabolic response elicited by acute nutritional and acute exercise challenges,
  2. to elucidate biological mechanisms underlying inter-individual heterogeneity in these responses,
  3. to predict prospective weight loss over the intervention using heterogeneous metabolic responses to acute challenges

详细描述

The objectives of this study are 1) to characterize dynamic metabolic response elicited by acute nutritional and acute exercise challenges, 2) to elucidate biological mechanisms underlying inter-individual heterogeneity in these responses, and 3) to predict prospective weight loss over the intervention using heterogeneous metabolic responses to acute challenges.

In this study, 84 overweight or obese participants (BMI ≥ 24 kg/m2) and 28 normal weight participants (18.5 ≤ BMI<24 kg/m2) will be recruited and receive 12-week caloric-restriction dietary or weight maintenance interventions. Before and after the 12-week interventions, metabolic homeostasis will be used to characterize metabolic health and to be determined using comprehensive measurements of dynamic changes in postprandial metabolic responses (including energy metabolism, multiple clinical biomarkers, metabolomic signatures, gut microbiota, genetic signatures etc.) after standardized mixed macronutrient tolerance test (75 g glucose, 60 g fat and 20 g protein) in whole room indirect calorimeter under both resting and exercise conditions. In addition, data from dietary intake, anthropometric measurements, body composition, psychosocial measures, behavior questionnaires and 14-day continuous glucose monitoring will also be collected to characterize metabolic homeostasis. During the interventions, participants will receive personalized dietary advice, behavior guidance and nutritional and lifestyle education by dietitian and physicians. APP-connected wearable devices will be utilized to monitor their dietary intakes, physical activities and sleep conditions, and an application-connected scale will be used to monitor their weight changes during interventions. The study's protocol has been approved by the Ethics Committee of Sir Run Run Shaw Hospital.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
20 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •20-70 years of age, inclusive
  • •BMI ≥ 24kg/m2
  • •Not in other clinical studies currently or in the past three months

排除标准

  • •Fasting glucose >7.0mmol/L or diagnosed diabetes or taking insulin or other blood glucose-lowering drugs
  • •Blood pressure > 160/100 mmHg; diagnosed phase II or III hypertension or cannot decrease SBP under 160mmHg after anti-hypertension drugs
  • •Fasting blood TG≥ 5.7 mmol/L or fasting LDL-C≥ 4.9 mmol/L or cannot control TG < 5.7 mmol/L or LDL-C < 4.9 mmol/L after taking lipid lowering drugs
  • •Pregnant or lactating
  • •Attempting to change body weight in the past 3 months
  • •Use of antibiotic in the preceding 3 months for 3-serial days
  • •Use of estrogen therapy or hormonal drugs in the preceding 6 months
  • •History of alcohol abuse or other substance abuse (Alcohol abuse is defined as regular alcohol consumption > 40 g/day for females or > 80 g/day for males)
  • •Severe renal disease or liver disease
  • •Severe gastrointestinal diseases
  • •Surgical events preceding 1 year (except appendicitis or hernia surgery)
  • •Severe cardiovascular or cerebrovascular diseases
  • •Implantation of heart stent or any device containing metal material
  • •Cancer or receiving radiotherapy and chemotherapy within 5 years
  • •Hyperthyroidism or hypothyroidism
  • •Suffering from AIDS, hepatitis A, hepatitis B and other infectious diseases
  • •Claustrophobia
  • •Physical disability
  • •Any mental disorders or current use of antidepressants
  • •Cognitive disability

研究组 & 干预措施

Healthy Comparators

Placebo Comparator

They will receive general lifestyle and nutritional education.

干预措施: General lifestyle and nutritional education (Behavioral)

Overweight/Obese Group

Experimental

They will receive personalized nutritional and lifestyle weight reduction intervention including dietary advice, behavior guidance and nutritional and lifestyle education by dietitian and physicians.

干预措施: Personalized nutritional and lifestyle weight reduction intervention (Behavioral)

结局指标

主要结局

Fasting and postprandial energy metabolic response at baseline and post-intervention

时间窗: Baseline and Week 12

Energy metabolism is characterized by four primary indicators: energy expenditure (EE), respiratory quotient (RQ), carbohydrate oxidation rate (CarbOx), and fat oxidation rate (FatOx). EE denotes the rate of energy expenditure per minute (typically expressed in kcal/min). RQ, defined as the ratio of carbon dioxide produced to oxygen consumed (VCO₂/VO₂), reflects whole-body substrate utilization. CarbOx and FatOx represent the respective oxidation rates of carbohydrate and fat, quantifying the contribution of each macronutrient to total energy production.

次要结局

  • Change from Baseline in Body Mass Index at 12 Weeks(Baseline and Week 12)
  • Change from Baseline in Hip Circumference at 12 Weeks(Baseline and Week 12)
  • Change from Baseline in Body Weight at 12 Weeks(Baseline and Week 12)
  • Change from Baseline in Waist Circumference at 12 Weeks(Baseline and Week 12)
  • Change from Baseline in Blood Pressure at 12 Weeks(Baseline and Week 12)
  • Change from Baseline in Heart Rate at 12 Weeks(Baseline and Week 12)
  • Change from Baseline in Body Composition at 12 Weeks(Baseline and Week 12)
  • Change from Baseline in Energy Expenditure at 12 Weeks(Baseline and Week 12)
  • Change from Baseline in Glucose Homeostasis at 12 Weeks(Baseline and Week 12)
  • Change from Baseline in Glucose at 12 Weeks(Baseline and Week 12)
  • Change from Baseline in Insulin Indices at 12 Weeks(Baseline and Week 12)
  • Change from Baseline in Respiratory Quotient at 12 Weeks(Baseline and Week 12)
  • Change from Baseline in C-peptide at 12 Weeks(Baseline and Week 12)
  • Change from Baseline in Lipid Parameters at 12 Weeks(Baseline and Week 12)
  • Change from Baseline in Protein and Amino Acids Metabolites at 12 Weeks(Baseline and Week 12)
  • Change from Baseline in Inflammatory Biomarkers and Cytokines at 12 Weeks(Baseline and Week 12)
  • Change from Baseline in Gastrointestinal Hormones at 12 Weeks(Baseline and Week 12)
  • Change from Baseline in Adipokines at 12 Weeks(Baseline and Week 12)
  • Single nucleotide polymorphism (SNPs)(Baseline)
  • Change from Baseline in Metabolomics at 12 Weeks(Baseline and Week 12)
  • Gut microbiota 16S rDNA sequencing(Baseline and Week 12)
  • Change from Baseline in Cell Adhesion Molecules at 12 Weeks(Baseline and Week 12)

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Xu Lin

Principal Investigator

Chinese Academy of Sciences

研究点 (1)

Loading locations...

相似试验